Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-25-010052
Filing Date
2025-03-12
Accepted
2025-03-12 16:22:24
Documents
62
Period of Report
2025-01-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1211917
2 ex31-1.htm EX-31.1 17142
3 ex31-2.htm EX-31.2 17146
4 ex32-1.htm EX-32.1 6596
5 ex32-2.htm EX-32.2 6898
  Complete submission text file 0001493152-25-010052.txt   6295747

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE bctx-20250131.xsd EX-101.SCH 41454
7 XBRL CALCULATION FILE bctx-20250131_cal.xml EX-101.CAL 40773
8 XBRL DEFINITION FILE bctx-20250131_def.xml EX-101.DEF 246864
9 XBRL LABEL FILE bctx-20250131_lab.xml EX-101.LAB 330045
10 XBRL PRESENTATION FILE bctx-20250131_pre.xml EX-101.PRE 291180
64 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1184088
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: 10-Q | Act: 34 | File No.: 001-40101 | Film No.: 25732044
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)